can tirzepatide cause abdominal pain Common Side Effects Demystified Tirzepatide Dosing - A Patient

This phase 3 randomized controlled trial enrolled participants with BMI over 24 kg/m (the obesity threshold in Asian populations) or BMI over 28 kg/m with comorbidities

Moreover, the percentage of participants in clinical trials who stopped the treatment due to AE was 515% with most of the new agents, and this percentage was up to 2030% with some of GLP-1/glucagon RA in phase 2 trials so a considerable proportion of people may not be able to tolerate the new obesity pharmacotherapies or may be unable to titrate them to the higher and most effective doses

high work or caregiving stress

Prior authorization is still required and typically asks for documentation of prior MI, stroke, or symptomatic peripheral arterial disease plus current BMI